Answer: a. Haploid spores are released to form zygotes, which grow into gametophytes.
A fern has two different stages of the life cycle; the sporophyte and gametophyte. In the sporophyte, spores are released. After this life cycle comes the gametophyte or the sexual phase, <span>haploid spores are released to form zygotes, which grow into gametophytes. </span>
Answer:
hemoglobin
Explanation:
Cytoplasm of RBCs contain large amount of hemoglobin which contain iron binds to haem group. it carry and transport oxygen from lungs to all parts of body and return carbondioxide back to the lungs from the different tissues.
Normal level of hemoglobin for men= 13.5 to 17.5 g/dl and for women =12.0 to 15.5 g/dl
Low level of hemoglobin is the indication of anemia
Answer:
(d). B-cells.
Explanation:
Adaptive immunity can be described as immunity which develops in response to exposure to a pathogen (or foreign molecule). throughout the life. It is divided into two types, humoral immunity and cell-mediated immunity.
Humoral immunity is mediated by B cells that secrete antibodies against particular antigens. These antibodies recognize and neutralize the antigens and activate cell-mediated immunity, which is mediated by T cells.
Thus, the correct answer is option (d).
Answer:
Explanation:
The more similar the two species are, the more their niche overlaps and the more competition there is.
<em>The most interesting results obtained in animal models of passive immunotherapies developed according to the “amyloid-beta cascade hypothesis” and the “Tau hypothesis” are monoclonal antibodies that directly or indirectly target Aβ plaques or neurofibrillary tangles. Unfortunately, these therapeutic antibodies cannot replicate their promising effects on humans at the clinical phase. Despite this, we still hope to learn from these failures and to explore new pathways. The great effects obtained in animals with passive immunotherapy suggest that this technology may be an important key to curative treatment. The remaining challenge is to find a way to achieve the same encouraging results for humans. Alzheimacy expects to join hands with global partners to focus on the development of therapeutic antibodies for Alzheimer’s disease (AD) and continue to fight against this disease.</em>
<em>https://www.creativebiomart.net/alzheimacy/therapeutics/therapeutic-antibody/</em>
